Lipoprotein levels are associated with incident hypertension in older adults

Journal of the American Geriatrics Society

Volumn 52, Issue 6, 2004, Pages 916-921

  Wildman, Rachel P ^a   Sutton Tyrrell, Kim ^a   Newman, Anne B ^a   Bostom, Andrew ^b   Brockwell, Sarah ^a   Kuller, Lewis H ^a  

^a UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^b MEMORIAL HOSPITAL OF RHODE ISLAND   (United States)

Author keywords

Elderly; High density lipoprotein; Hypertension; Incidence; Systolic blood pressure

Indexed keywords

ANTIHYPERTENSIVE AGENT; APOLIPOPROTEIN A1; APOLIPOPROTEIN A2; APOLIPOPROTEIN B; HIGH DENSITY LIPOPROTEIN 2 CHOLESTEROL; HIGH DENSITY LIPOPROTEIN 3 CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

AGED; ARTICLE; COHORT ANALYSIS; DIASTOLIC BLOOD PRESSURE; DISEASE ASSOCIATION; ELDERLY CARE; FEMALE; HUMAN; HYPERTENSION; INCIDENCE; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PROSPECTIVE STUDY; SYSTOLIC BLOOD PRESSURE; SYSTOLIC HYPERTENSION;

AGED; AGED, 80 AND OVER; CHOLESTEROL, HDL; FEMALE; HUMANS; HYPERTENSION; INCIDENCE; LIPOPROTEINS; MALE; MIDDLE AGED; RISK FACTORS;

EID: 2942750150     PISSN: 00028614     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1532-5415.2004.52258.x     Document Type: Article

References (40)

1. Kannel WB. Elevated systolic blood pressure as a cardiovascular risk factor. Am J Cardiol 2000;85:251-255.
2. Cushman WC. The clinical significance of systolic hypertension. Am J Hypertens 1998;11:182S-185S.
3. Lackland DT, Egan BM. The dominant role of systolic hypertension as a vascular risk factor: Evidence from the southeastern United States. Am J Med Sci 1999;318:365-368.
4. Black HR. The paradigm has shifted, to systolic blood pressure. Hypertension 1999;34:386-387.
5. Harris T, Cook EF, Kannel W et al. Blood pressure experience and risk of cardiovascular disease in the elderly. Hypertension 1985;7:118-124.
6. Kannel WB, Wolf PA, McGee DL et al. Systolic blood pressure, arterial rigidity, and risk of stroke. The Framingham Study. JAMA 1981;245:1225-1229.
7. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group. JAMA 1991;265:3255-3264.
8. Staessen J, Amery A, Fagard R. Isolated systolic hypertension in the elderly. J Hypertens 1990;8:393-405.
9. The fifth report of the Joint National Committee on Detection Evaluation, and Treatment of High Blood Pressure (JNC-V). Arch Intern Med 1993;153:154-183.
10. The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Arch Intern Med 1997;157:2413-2446.
11. Staessen JA, Fagard R, Thijs L et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Lancet 1997;350:757-764.
12. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vresus usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002;288:2998-3007.
13. Wing LM, Reid CM, Ryan P et al. A comparison of outcomes with angiotensin-converting enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med 2003;348:583-589.
14. Burt VL, Whelton P, Roccella EJ et al. Prevalence of hypertension in the U.S. adult population. Results from the Third National Health and Nutrition Examination Survey, 1988-91. Hypertension 1995;25:305-313.
15. Srinivas K, Bhaskar MV, Aruna Kumari R et al. Antioxidants, lipid peroxidation and lipoproteins in primary hypertension. Indian Heart J 2000;52:285-288.
16. Flesch M, Sachinidis A, Ko YD et al. Plasma lipids and lipoproteins and essential hypertension. Clin Invest 1994;72:944-950.
17. Catalano M, Aronica A, Carzaniga G et al. Serum lipids and apolipoproteins in patients with essential hypertension. Atherosclerosis 1991;87:17-22.
18. Lemne C, Hamsten A, Karpe F et al. Dyslipoproteinemic changes in borderline hypertension. Hypertension 1994;24:605-610.
19. Macmahon SW, Macdonald GJ, Blacket RB. Plasma lipoprotein levels in treated and untreated hypertensive men and women. Arterosclerosis 1985;5:391-396.
20. Sutton-Tyrrell K, Bostom A, Selhub J et al. High homocysteine levels are independently related to isolated systolic hypertension in older adults. Circulation 1997;96:1745-1749.
21. Wilking SV, Belanger A, Kannel WB et al. Determinants of isolated systolic hypertension. JAMA 1988;260:3451-3455.
22. Hill MN, Russell RP. Revision of guidelines for high blood pressure management: JNC IV Joint National Committee on Detection, Evaluation and Treatment of High Blood Pressure. Md Med J 1988;37:698-701.
23. Petrovitch H, Byington R, Bailey G et al. Systolic Hypertension in the Elderly Program (SHEP) Part 2: Screening and recruitment. Hypertension 1991;17:II16-II23.
24. Black H, Curb JD, Pressel S et al. Systolic Hypertension in the Elderly Program (SHEP): Baseline characteristics of the randomized sample. Hypertension 1991;17:II-1-II-171.
25. Sutton-Tyrrell K, Evans RW, Meilahn E et al. Lipoprotein (a) and peripheral atherosclerosis in older adults. Atherosclerosis 1996;122:11-19.
26. Stein MW. Determination with hexokinase and glucose-6-phophate dehydrogenase. In: Bergmeyer HU, ed. Methods of Enzymatic Analysis. New York: Academic Press, 1963, p. 117.
27. Bucolo G, David H. Quantitative determination of serum triglycerides by the use of enzymes. Clin Chem 1973;19:476-482.
28. Folstein MF, Folstein SE, McHugh PR. 'Mini-mental state'. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-198.
29. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-481.
30. Cox DR. Regression models and life tables (with discussion). J R Stat Soc B 1972;34:187-220.
31. Vasan RS, Larson MG, Leip EP et al. Assessment of frequency of progression to hypertension in non-hypertensive participants in the Framingham Heart Study: A cohort study. Lancet 2001;358:1682-1686.
32. Mahley RW, Weisgraber KH et al. Disorders of lipid metabolism. In: Larsen PR, Kronenberg HM, Melmed S, eds. Williams Textbook of Endocrinology, 10th Ed. Philadelphia, PA: W.B. Saunders Company, 2003, pp 1642-1706.
33. Pannier BM, Cambillau MS, Vellaud V et al. Abnormalities of lipid metabolism and arterial rigidity in young subjects with borderline hypertension. Clin Invest Med 1994;17:42-51.
34. Havlik RJ, Brock D, Lohman K et al. High-density lipoprotein cholesterol and vascular stiffness at baseline in the activity counseling trial. Am J Cardiol 2001;87:104-107.
35. Sutton-Tyrrell K, Newman A, Simonsick EM et al. Aortic stiffness is associated with visceral adiposity in older adults enrolled in the study of health, aging, and body composition. Hypertension 2001;38:429-433.
36. Nesto RW, Libby P. Diabetes mellitus and the cardiovascular system. In: Braunwald E, Libby P, Zipes DD et al., eds. Heart Disease: A Textbook of Cardiovascular Medicine. Philadelphia, PA: W.B. Saunders Co, 2001, pp 2133-2150.
37. Dluhy RG, Williams GH. Endocrine Hypertension. In: Wilson JD, ed. Williams Textbook of Endocrinology. Philadelphia, PA: W.B. Saunders Co, 1998, pp 729-750.
38. Bagdade JD, Buchanan WF, Pollare T et al. Abnormal lipoprotein phospholipid composition in patients with essential hypertension. Atherosclerosis 1995;117:209-215.
39. Kannel WB, Gordan T. Evaluation of cardiovascular risk in the elderly: The Framingham Study. Bull N Y Acad Med 1978;54:573-591.
40. Galarza CR, Alfie J, Waisman GD et al. Diastolic pressure underestimates age-related hemodynamic impairment. Hypertension 1997;30:809-816.